Neurology Daily Report: 01/17/2024
Multiple Sclerosis
A phase II randomized controlled trial (RCT) will investigate an Internet-delivered behavioral intervention targeting lifestyle physical activity (LPA) for improving cognitive processing speed (CPS) in 300 persons with mild multiple sclerosis (MS)-related ambulatory impairment and impaired CPS (1). The primary outcome is the raw oral Symbol Digit Modalities Test for CPS, with secondary outcomes including learning/memory and patient-reported outcomes. The study aims to provide Class I evidence for the efficacy of this intervention in improving CPS in MS patients.
Reference
Motl RW, Sandroff BM, Benedict RHB, Aldunate R, Cutter G, Barron E. Internet-delivered lifestyle physical activity intervention for cognitive processing speed in multiple sclerosis. Contemp Clin Trials. 2024 Jan 17:107446. doi: 10.1016/j.cct.2024.107446. Epub ahead of print. PMID: 38242351.
Status Epilepticus and Rare Epileptic Disorders
A phase 1 single-group assignment study investigated the effect of intravenous ganaxolone in 36 healthy volunteers with status epilepticus and rare epileptic disorders and found that ganaxolone was generally well tolerated and demonstrated suitable pharmacokinetic and pharmacodynamic properties to treat SE (1).
Reference
Gasior M, Husain A, Barra ME, Raja SM, MacLeod D, Guptill JT, Vaitkevicius H, Rybak E. Intravenous Ganaxolone: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability in Healthy Adults. Clin Pharmacol Drug Dev. 2024 Jan 17. doi: 10.1002/cpdd.1365. Epub ahead of print. PMID: 38231434.